Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic Hepatitis
随机安慰剂对照预试验以确定 IL22 激动剂 (F-652) 对酒精性肝炎患者的疗效
基本信息
- 批准号:10202402
- 负责人:
- 金额:$ 7.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-22 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:Adrenal Cortex HormonesAgonistAlcoholic HepatitisAntioxidantsApoptoticCessation of lifeClinicClinical ResearchConduct Clinical TrialsDataDevelopmentDiseaseDoseDrug KineticsEnvironmentFutureGroup PracticeInvestigationLinkLiverMorbidity - disease ratePatient RecruitmentsPatientsPatternPentoxifyllinePharmacodynamicsPhasePilot ProjectsPlacebo ControlPlacebosPositioning AttributePrednisoneRandomizedRandomized Controlled TrialsResearchResearch PersonnelSafetySerious Adverse EventSignal TransductionSteroidsSystemTestingantimicrobialarmbaseclinical investigationdrug efficacyfollow-upimprovedinnovationinterleukin-22liver cell proliferationliver transplantationmortalitynovelnovel therapeuticspharmacokinetics and pharmacodynamicsphase 3 studypilot trialprimary endpointrandomized placebo controlled studysecondary endpointsuccesstherapeutic developmenttherapeutically effective
项目摘要
PROJECT SUMMARY/ABSTRACT
Alcoholic hepatitis (AH) is a leading cause of liver-related morbidity and mortality with a remarkable paucity of
effective therapeutics. F-652, an IL-22 agonist, is a promising agent to treat patients with AH because of its
antioxidant, anti-apoptotic, anti-steatotic, anti-microbial, and pro-proliferative effects that have been
demonstrated in various experimental systems. A pilot study from our group in patients with AH has confirmed
safety and suggested efficacy of F-652, with no worrisome pharmacodynamic or pharmacokinetic patterns.
Based on the encouraging results from the pilot study, this application represents the next step to confirm
efficacy of the IL-22 agonist in patients with AH. The aims of this proposal are: 1. Determine the efficacy and
confirm the safety of an IL-22 agonist (F-652) in a randomized, placebo-controlled study in patients
with AH and MELD score 11-20 as demonstrated by improved MELD scores at 90 days. Patients with AH
and MELD score 11-20 (thus not candidates for the trial described in our linked application to RFA-AA-18-002)
will undergo a 1:1 randomization into an IL-22 agonist arm or a placebo (control) arm. Three doses of the IL-22
agonist or placebo will be administered at approximately 5-day intervals. The primary endpoint is improvement
(reduction) in MELD score by >25% at 90 days. Secondary endpoints include 30- and 90-day survival; Lille
score; and safety as determined by absence of serious adverse events (SAE) at 90 days. 2. Determine the
efficacy and confirm the safety of an IL-22 agonist (F-652) in a randomized, placebo-controlled study in
patients with AH and MELD score 21-28 as demonstrated by improved MELD scores at 90 days.
Patients with AH with contraindication to steroids (thus not candidates for the trial described in our linked
application to RFA-AA 18-002) and MELD score 21-28 will undergo a 2:1 randomization into an IL-22 agonist
arm or a placebo (control) arm. Three doses of the IL-22 agonist or placebo will be administered at
approximately 5-day intervals. Secondary endpoints include 30- and 90-day survival; Lille score; and safety as
determined by absence of SAE up to 90 days. We believe a pilot randomized controlled trial is a logical
extension of our preliminary studies which demonstrated safety and possible efficacy of the IL-22 agonist in
patients with AH. The investigators are uniquely positioned to perform the proposed study given substantial
breadth and depth of expertise related to AH, clinical trial conduct, and therapeutic development.
项目摘要/摘要
酒精性肝炎(AH)是肝脏相关发病率和死亡率的主要原因,
有效的治疗方法。F-652,一种IL-22激动剂,是一种有希望的治疗AH患者的药物,因为其
抗氧化、抗凋亡、抗脂肪变性、抗微生物和促增殖作用,
在不同的实验系统中得到验证。我们小组在AH患者中进行的一项初步研究证实,
F-652的安全性和建议疗效,没有令人担忧的药效学或药代动力学模式。
基于试点研究的令人鼓舞的结果,该应用程序代表了下一步确认
IL-22激动剂在AH患者中的疗效。本提案的目的是:1.确定疗效,
在一项随机、安慰剂对照研究中证实了IL-22激动剂(F-652)的安全性
AH和MELD评分为11-20,如90天时MELD评分改善所证明。AH患者
和MELD评分11-20(因此不是我们与RFA-AA-18-002相关的申请中所述试验的候选人)
将进行1:1随机化至IL-22激动剂组或安慰剂(对照)组。
激动剂或安慰剂将以大约5天的间隔施用。主要终点是改善
在90天时,MELD评分降低>25%。次要终点包括30天和90天生存期;里尔
评分;以及通过在90天时不存在严重不良事件(SAE)确定的安全性。2.确定
在一项随机、安慰剂对照研究中,
AH和MELD评分21-28的患者,如90天时MELD评分改善所证明的。
有类固醇禁忌症的AH患者(因此不是我们的链接中描述的试验的候选人)
应用于RFA-AA 18-002)和MELD评分21-28的受试者将以2:1随机化至IL-22激动剂中
三个剂量的IL-22激动剂或安慰剂将在10天内施用。
大约5天的间隔。次要终点包括30天和90天生存期、里尔评分和安全性,
根据90天内无SAE确定。我们相信一个试点随机对照试验是一个合乎逻辑的
我们的初步研究的扩展,这些研究证明了IL-22激动剂在以下方面的安全性和可能的疗效:
AH患者。研究者处于独特的地位,可以进行拟议的研究,
与AH、临床试验实施和治疗开发相关的专业知识的广度和深度。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
VIJAY H. SHAH其他文献
VIJAY H. SHAH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('VIJAY H. SHAH', 18)}}的其他基金
Liver Cirrhosis Network: Clinical Research Center - Mayo Clinic
肝硬化网络:临床研究中心 - 梅奥诊所
- 批准号:
10487453 - 财政年份:2021
- 资助金额:
$ 7.5万 - 项目类别:
Liver Cirrhosis Network: Clinical Research Center - Mayo Clinic
肝硬化网络:临床研究中心 - 梅奥诊所
- 批准号:
10310667 - 财政年份:2021
- 资助金额:
$ 7.5万 - 项目类别:
Liver Cirrhosis Network: Clinical Research Center - Mayo Clinic
肝硬化网络:临床研究中心 - 梅奥诊所
- 批准号:
10700154 - 财政年份:2021
- 资助金额:
$ 7.5万 - 项目类别:
Assessment of Alcoholic Hepatitis with Multiparametric Magnetic Resonance Elastography
多参数磁共振弹性成像评估酒精性肝炎
- 批准号:
10459414 - 财政年份:2018
- 资助金额:
$ 7.5万 - 项目类别:
Assessment of Alcoholic Hepatitis with Multiparametric Magnetic Resonance Elastography
多参数磁共振弹性成像评估酒精性肝炎
- 批准号:
10205237 - 财政年份:2018
- 资助金额:
$ 7.5万 - 项目类别:
Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic Hepatitis
随机安慰剂对照预试验以确定 IL22 激动剂 (F-652) 对酒精性肝炎患者的疗效
- 批准号:
9791141 - 财政年份:2018
- 资助金额:
$ 7.5万 - 项目类别:
Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic Hepatitis
随机安慰剂对照预试验以确定 IL22 激动剂 (F-652) 对酒精性肝炎患者的疗效
- 批准号:
10449219 - 财政年份:2018
- 资助金额:
$ 7.5万 - 项目类别:
Assessment of Alcoholic Hepatitis with Multiparametric Magnetic Resonance Elastography
多参数磁共振弹性成像评估酒精性肝炎
- 批准号:
9791139 - 财政年份:2018
- 资助金额:
$ 7.5万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 7.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 7.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 7.5万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 7.5万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 7.5万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 7.5万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 7.5万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 7.5万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 7.5万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 7.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)